Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2008 2
2009 3
2010 1
2011 2
2012 1
2013 3
2014 5
2015 4
2016 3
2017 7
2018 12
2019 4
2020 1
2021 3
2022 3
2023 4
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

56 results

Results by year

Filters applied: . Clear all
Page 1
Management of adult patients with CMML undergoing allo-HCT: recommendations from the EBMT PH&G Committee.
Onida F, Gagelmann N, Chalandon Y, Kobbe G, Robin M, Symeonidis A, de Witte TM, Itzykson RA, Jentzsch M, Platzbecker U, Santini V, Sanz GF, Scheid C, Solary E, Valent P, Greco R, Sánchez-Ortega I, Yakoub-Agha I, Pleyer L. Onida F, et al. Among authors: pleyer l. Blood. 2024 Mar 17:blood.2023023476. doi: 10.1182/blood.2023023476. Online ahead of print. Blood. 2024. PMID: 38493484
Oncogenic MTOR signaling axis compensates BTK inhibition in a Chronic Lymphocytic Leukemia patient with Richter Transformation: A Case Report and Review of the Literature.
Parigger T, Drothler S, Scherhäufl C, Gassner FJ, Schubert M, Steiner M, Höpner JP, Hödlmoser A, Schultheis L, Abu Bakar A, Neureiter D, Pleyer L, Egle A, Greil R, Geisberger R, Zaborsky N. Parigger T, et al. Among authors: pleyer l. Acta Haematol. 2024 Feb 24. doi: 10.1159/000537791. Online ahead of print. Acta Haematol. 2024. PMID: 38402867
Cox proportional hazards deep neural network identifies peripheral blood complete remission to be at least equivalent to morphologic complete remission in predicting outcomes of patients treated with azacitidine-A prospective cohort study by the AGMT.
Pleyer L, Vaisband M, Drost M, Pfeilstöcker M, Stauder R, Heibl S, Sill H, Girschikofsky M, Stampfl-Mattersberger M, Pichler A, Hartmann B, Petzer A, Schreder M, Schmitt CA, Vallet S, Melchardt T, Zebisch A, Pichler P, Zaborsky N, Machherndl-Spandl S, Wolf D, Keil F, Hasenauer J, Larcher-Senn J, Greil R. Pleyer L, et al. Am J Hematol. 2023 Nov;98(11):1685-1698. doi: 10.1002/ajh.27046. Epub 2023 Aug 7. Am J Hematol. 2023. PMID: 37548390
Myeloid NGS Analyses of Paired Samples from Bone Marrow and Peripheral Blood Yield Concordant Results: A Prospective Cohort Analysis of the AGMT Study Group.
Jansko-Gadermeir B, Leisch M, Gassner FJ, Zaborsky N, Dillinger T, Hutter S, Risch A, Melchardt T, Egle A, Drost M, Larcher-Senn J, Greil R, Pleyer L. Jansko-Gadermeir B, et al. Among authors: pleyer l. Cancers (Basel). 2023 Apr 14;15(8):2305. doi: 10.3390/cancers15082305. Cancers (Basel). 2023. PMID: 37190237 Free PMC article.
Health-Related Quality of Life as Assessed by the EQ-5D-5L Predicts Outcomes of Patients Treated with Azacitidine-A Prospective Cohort Study by the AGMT.
Pleyer L, Heibl S, Tinchon C, Vallet S, Schreder M, Melchardt T, Stute N, Föhrenbach Quiroz KT, Leisch M, Egle A, Scagnetti L, Wolf D, Beswick R, Drost M, Larcher-Senn J, Grochtdreis T, Vaisband M, Hasenauer J, Zaborsky N, Greil R, Stauder R. Pleyer L, et al. Cancers (Basel). 2023 Feb 22;15(5):1388. doi: 10.3390/cancers15051388. Cancers (Basel). 2023. PMID: 36900181 Free PMC article.
The Class IIA Histone Deacetylase (HDAC) Inhibitor TMP269 Downregulates Ribosomal Proteins and Has Anti-Proliferative and Pro-Apoptotic Effects on AML Cells.
Urwanisch L, Unger MS, Sieberer H, Dang HH, Neuper T, Regl C, Vetter J, Schaller S, Winkler SM, Kerschbamer E, Weichenberger CX, Krenn PW, Luciano M, Pleyer L, Greil R, Huber CG, Aberger F, Horejs-Hoeck J. Urwanisch L, et al. Among authors: pleyer l. Cancers (Basel). 2023 Feb 7;15(4):1039. doi: 10.3390/cancers15041039. Cancers (Basel). 2023. PMID: 36831382 Free PMC article.
The ABNL-MARRO 001 study: a phase 1-2 study of randomly allocated active myeloid target compound combinations in MDS/MPN overlap syndromes.
Moyo TK, Mendler JH, Itzykson R, Kishtagari A, Solary E, Seegmiller AC, Gerds AT, Ayers GD, Dezern AE, Nazha A, Valent P, van de Loosdrecht AA, Onida F, Pleyer L, Cirici BX, Tibes R, Geissler K, Komrokji RS, Zhang J, Germing U, Steensma DP, Wiseman DH, Pfeilstöecker M, Elena C, Cross NCP, Kiladjian JJ, Luebbert M, Mesa RA, Montalban-Bravo G, Sanz GF, Platzbecker U, Patnaik MM, Padron E, Santini V, Fenaux P, Savona MR; MDS/MPN International Working Group. Moyo TK, et al. Among authors: pleyer l. BMC Cancer. 2022 Sep 24;22(1):1013. doi: 10.1186/s12885-022-10073-w. BMC Cancer. 2022. PMID: 36153475 Free PMC article. Clinical Trial.
Adverse Events in 1406 Patients Receiving 13,780 Cycles of Azacitidine within the Austrian Registry of Hypomethylating Agents-A Prospective Cohort Study of the AGMT Study-Group.
Leisch M, Pfeilstöcker M, Stauder R, Heibl S, Sill H, Girschikofsky M, Stampfl-Mattersberger M, Tinchon C, Hartmann B, Petzer A, Schreder M, Kiesl D, Vallet S, Egle A, Melchardt T, Piringer G, Zebisch A, Machherndl-Spandl S, Wolf D, Keil F, Drost M, Greil R, Pleyer L. Leisch M, et al. Among authors: pleyer l. Cancers (Basel). 2022 May 17;14(10):2459. doi: 10.3390/cancers14102459. Cancers (Basel). 2022. PMID: 35626063 Free PMC article.
Scalable Enrichment of Immunomodulatory Human Acute Myeloid Leukemia Cell Line-Derived Extracellular Vesicles.
Binder HM, Maeding N, Wolf M, Cronemberger Andrade A, Vari B, Krisch L, Gomes FG, Blöchl C, Muigg K, Poupardin R, Raninger AM, Heuser T, Obermayer A, Ebner-Peking P, Pleyer L, Greil R, Huber CG, Schallmoser K, Strunk D. Binder HM, et al. Among authors: pleyer l. Cells. 2021 Nov 26;10(12):3321. doi: 10.3390/cells10123321. Cells. 2021. PMID: 34943829 Free PMC article.
56 results